Home › Mga Karamdaman ng Isip › New Jersey
Pag-aaral pangklinika para sa Mga Karamdaman ng Isip sa New Jersey
7 pag-aaral para sa Mga Karamdaman ng Isip ang naghahanap ng mga kalahok sa mga site sa New Jersey.
Mga Lungsod sa New Jersey
Opisyal na teksto ng pag-aaral (English)
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Clinical Site, West Long Branch
Nagre-recruitPhase 2
Edad 55 hanggang 90 · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06887192A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Marlton
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07459647A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
- CenExel AMRI, Toms River
Nagre-recruitPhase 1
Edad 50 hanggang 85 · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT06297590A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- Clinilabs, LLC, Eatontown
- Bio Behavioral Health, Toms River
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update May 11, 2026 · NCT06524830A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
- Vistagen Clinical Site, Toms River
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Peb 5, 2026 · NCT06809179Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
- Rutgers University Primary Care Clinics, New Brunswick
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 3, 2026 · NCT06387290Open-label Extension Study in Participants With Early Alzheimer's Disease
- GSK Investigational Site, Toms River
Nagre-recruitPhase 2
Edad 50 hanggang 85 · Lahat ng kasarian · Na-update Peb 2, 2026 · NCT07105709Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.